Clenoliximab Biosimilar, Anti-human CD4 Monoclonal Antibody | C042P

Catalog No.	C042P
Product Name	Clenoliximab Biosimilar, Anti-human CD4 Monoclonal Antibody | C042P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	cluster of differentiation 4, CD-4
Summary	Recombinant Humanized IgG4 Monoclonal Antibody.
Source/Host	The anti-human CD4 monoclonal antibody clenoliximab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade clenoliximab biosimilar specifically binds to the human CD4.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by clenoliximab.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade clenoliximab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Clenoliximab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C042P: Clenoliximab Biosimilar, Anti-human CD4 Monoclonal Antibody

Recombinant Humanized IgG4 Monoclonal Antibody.

Background

Clenoliximab Biosimilar uses the same protein sequences as the therapeutic antibody clenoliximab.

Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

Clenoliximab is a macaque-human chimeric monoclonal antibody (immunoglobulin G4)that binds specifically to the CD4 receptor present on T-lympocytes (Helper T lymphocytes). CD-4 lymphocytes are implicated in the pathogenesis of rheumatoid arthritis (RA). Clenoliximab coats the CD4 T-lymphocytes and thus down-modulates the CD4 T-lympocytes in a dose and concentration-dependent manner without decreasing the amount of CD4 T-lympocytes in circulation.

Please remember our product information: Clenoliximab Biosimilar, CD4 Monoclonal Antibody: C042P Syd Labs

No more offers for this product!